As we move through Spring 2026, women’s healthcare services across the UK continue to evolve in response to changing clinical demands, workforce pressures, and national healthcare priorities. AGHealth remain committed to supporting NHS teams with innovative diagnostics, induction solutions, and clinical implementation support designed to improve patient experience and operational efficiency. In this edition, we explore: The ongoing national Prostin shortage Latest development

The ongoing Prostin supply disruption is beginning to place significant pressure on induction of labour (IOL) services across the UK. As maternity teams work to maintain safe, effective care, many are reviewing and adapting their existing cervical ripening pathways. The current disruption impacts several commonly used prostaglandin options: Prostin® E2 3 mg vaginal tablets (pessary) Prostin® E2 1 mg/2.5 ml gel Prostin® E2 2 mg/2.5 ml gel How Maternity Units Are Responding to